The effect of vitamin D add-on therapy on the improvement of quality of life and clinical symptoms of patients with chronic spontaneous urticaria

Seyed Hesamedin Nabavizadeh,1,2 Soheila Alyasin,1,2 Hossein Esmaeilzadeh,1,2 Fereshteh Mosavat,2 Narjes Ebrahimi1

Abstract

Background: Chronic urticaria is a common distressing allergic skin disorder. Immune dysregulation, histamine release and mast cell degranulation are suggested as its underlying mechanisms.

Objective: Add-on therapy of vitamin D was evaluated in patients with chronic spontaneous urticaria to determine the quality of life and urticaria severity score.

Methods: In a prospective, double-blinded study, 80 participants with chronic spontaneous urticaria were randomized to low (4200 IU/week, group 1) and high (28,000 IU/week, group 2) vitamin D3 supplementation groups for 12 weeks. Demographic data; quality of life, urticaria severity and medication scores; 25-hydroxyvitamin D and anti-thyroid peroxidase antibody levels; and autologous serum skin test data were collected.

Results: Both groups showed significantly reduced total urticaria severity score; decrement in group 2 score was significant compared to group 1 at week 6 (P = 0.010). Quality of life score was also significantly reduced; decrement in group 2 score was significant compared to group 1 at both weeks 6 (P = 0.005) and 12 (P = 0.007). 25-hydroxyvitamin D levels were elevated significantly over the course of 12 weeks in both groups; however, the elevation in group 2 was significantly higher than group 1 at week 12 (P = 0.002). Medication score was significantly reduced, with no significant difference between groups. No association was observed between positive autologous serum skin test, angioedema and high level of Anti thyroperoxidase antibody with positive response to vitamin D.

Conclusion: Add-on therapy with vitamin D (28,000 IU/week) can be considered as a safe and potentially beneficial treatment in patients with chronic spontaneous urticaria.

Key words: Add-on Therapy, Chronic Urticaria, Clinical symptoms, Quality of life, Vitamin D

Introduction

Chronic urticaria (CU) is defined as daily presentation of wheals, angioedema or both that continuous for six weeks or more.1 It was reported that 10-20% of the general population experience at least one episode of urticaria and 1% of the general population experience CU.2 CU is presented as
urticarial wheals in 50% of the patients; 10% of the patients experience angioedema alone and wheal and angioedema coexist in 40% of the patients. Two types of CU are defined: chronic inducible urticaria and chronic spontaneous urticaria. The latter is defined as spontaneous presentation of wheal and/or angioedema without any specific trigger. The pathogenesis of CU has not been exactly defined. Increasing evidence suggest the role of auto immunity in CU pathogenesis. Autologous serum skin test (ASST) is applied as a simple and inexpensive in vivo screening test that determine histamine releasing factors in serum, including histamine releasing auto antibodies in CU. IgG thyroid auto antibodies (anti thyroid peroxidase (anti TPO) antibodies) were observed in 30% of CU cases, while the incidence of thyroid auto antibodies in the general population is 5-10%. The activation of ‘autoallergic’ mast cells through anti TPO was reported recently, while functional IgG antibodies against IgE or FcεR1 were also observed.

Based on EAACI/GA²LEN/EDF/WAO Guideline for urticarial management, second generation H1 antihistamines are the first line pharmacological therapy of CU and up dosing is recommended in case that clinical presentations persist. Omalizumab and cyclosporine are recommended as 3rd line therapy, applied once a week, on the clinical symptoms and quality of life (CU-QoL) questionnaires, considering the presence of angioedema, anti TPO antibody and ASST test positivity.

Methods
Study design
This is a randomized double blind clinical trial study, conducted 2016-18 in a tertiary referral center (Emam Reza Allergy Clinic affiliated with Shiraz University of Medical Sciences). Approved by local Ethics Committee of Shiraz University of Medical Sciences, this study was registered in ClinicalTrials.gov identifier (NCT number: NCT02873364). Sample size was determined using medCalc software and randomization was conducted with permuted block randomization method, with block size of four.

Inclusion criteria
Patients (≥ 12 years old) who fulfilled the CU criteria, diagnosed by allergy and immunology specialists were recruited: patients with the history of CU and/or angioedema, presented most of the week days, that had continued longer than 6 weeks, were included. Written Informed consent was obtained from each participant.

Exclusion criteria
Patients with one or more of the following criteria were excluded:
- Chronic inducible urticaria, hereditary/acquired angioedema, urticarial vasculitis, sarcoidosis, primary hyper parathyroidism, anaphylaxis, auto inflammatory syndromes, hypercalcemia (serum Ca level > 10.3 mg/dL and spot urine Ca level ≥ 30 mg/dL), 25(OH)D ≥ 200 ng/mL, renal failure (GFR < 50 mL/min/1.73 m³), renal lithiasis, malignancy, pregnancy, lactation and granulomatous disease.
- Nonsteroidal anti-inflammatory drugs (NSAIDs) and alcohol, as CU triggers, were prohibited throughout the study.

Intervention
Total of 80 patients were divided into two equal groups. Group 1 received low dose (4200 IU/week) and group 2 received higher doses (28000 IU/week) of vitamin D (as vitamin D₃ pearls), weekly, for 12 weeks. Trial profile is shown in Figure 1. Doses of vitamin D were selected based on the minimum and maximum safe dose for patients aged ≥ 12 years.

Baseline medication and medication score
Based on previous studies and guide lines, the baseline treatment protocol was designed as follows: 1) cetirizine: 10 mg/day up to 40 mg/day. 2) Montelukast: 5 mg/day (12-14 year
old patients) and 10 mg/day (patients > 14 years old), 3) Ranitidine: 4-5 mg/kg/day (12-14 year old patients) and 300 mg/day (patients > 14 years old). The dose of cetirizine was adjusted based on the USS. Short course of prednisolone therapy (maximum four days) was applied as rescue therapy. Patients received allergy medications for at least one month and medication score was calculated at this primary endpoint. Then vitamin D was added to the medication regimen and medication score was noted at weeks 6 and 12.

To calculate the medication score, points 2 and 8 were assigned for regular dose and 4 fold doses of antihistamines. Point 2, 6 and 8 were assigned for montelukast, hydroxychloroquine and cyclosporine (3 mg/Kg), respectively. Points 5, 10 and 15 were assigned for < 11 mg, 11-25 mg and > 25 mg of prednisolone, respectively.

Data collection
Demographic data and medical history were collected in the prepared data sheets. Baseline characteristics such as: age, gender, body mass index (BMI), ethnicity, educational level, duration of hives, vitamin D level at enrollment, atopy, angioedema, ASST, vitamin D supplementation prior to the study, smoking, alcohol consumption, NSAID exacerbation, thyroid diseases, anti-nuclear antibody (ANA), and anti TPO positive tests were recorded.

Questionnaires
The effectiveness of the treatment was evaluated based on the translated USS questionnaire and clinical symptoms were scored from 0 to 93. This questionnaire was applied since it is validated in Persian language. Higher USS scores indicate more severity of the disease. QoL was also assessed based on the translated and validated CU-QoL questionnaire. Higher QoL scores indicate lower quality of life. Questionnaires were filled at baseline, weeks 6 and 12.

Lab data
Blood samples were collected to assess serum levels of: albumin, Ca, P, thyroid stimulating hormone (TSH), antinuclear antibody (ANA), anti TPO, free thyroxin and renal function, at patient enrollment. Serum level of 25-hydroxyvitamin D (25(OH)D) was recorded to assess vitamin D level at three time points: at baseline, weeks 6 and 12. 25(OH)D level < 20 ng/mL, 20-30 ng/mL and ≥ 30 ng/mL were considered as deficient, insufficient and sufficient, respectively.

Spot urine was analyzed to determine urine Ca level in three groups 1 and 2, except for the number of patients with thyroid dysfunction, which was higher in group 2 (P = 0.040) (Table 1).

<table>
<thead>
<tr>
<th>Baseline characteristics</th>
<th>4200 IU/week (N = 35)</th>
<th>28000 IU/week (N = 34)</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (year)</td>
<td>40.02 (17-75)</td>
<td>39.94 (18-76)</td>
<td>0.978</td>
</tr>
<tr>
<td>Male sex</td>
<td>6 (17.14%)</td>
<td>5 (14.70%)</td>
<td>0.521</td>
</tr>
<tr>
<td>Female sex</td>
<td>29 (82.85%)</td>
<td>29 (85.29%)</td>
<td></td>
</tr>
<tr>
<td>Body mass index (Kg/m²)</td>
<td>26.87 ± 3.8</td>
<td>27.04 ± 4.3</td>
<td>0.871</td>
</tr>
<tr>
<td>White Asian race</td>
<td>35 (100%)</td>
<td>34 (100%)</td>
<td></td>
</tr>
</tbody>
</table>

Table 1. Baseline criteria of CU patients in this study

ASST test
ASST test was conducted as reported by Sabroe et al. Intradermal injection of normal saline and prick test of histamine (10 mg/mL) were considered as negative and positive controls. Following the intradermal injection of fresh autologous serum (0.05 mL), the red wheal diameter ≥ 15 mm (compared to negative control) was considered as positive.

Statistical analyzes
SPSS software was used to analyze data. Repeated measure ANOVA (RMANOVA) was applied to compare the difference in variables over time and between groups (P ≤ 0.05 was considered to be statistically significant). Since RMANOVA results showed minor differences, comparison between groups was performed in detail with student t-test, considering adjusted α (α = 0.017). To observe the differences within one group over the time, RMANOVA and Friedman’s test were used for parametric (QoL and USS scores) and non-parametric data (25(OH) level and medication score). To compare two paired groups (comparison of time points within one group), paired sample t-test and Wilcoxon signed rank analyzes were applied for parametric and non-parametric data. Baseline parameters were compared between groups with independent t-test and Mann-Whitney U-test, for parametric and non-parametric data; and P < 0.05 was considered as significant. Based on the analysis of questionnaires and the difference of vitamin D level between the groups that received high (28000 IU/week) and low dose (4200 IU/week) of vitamin D, the results of high dose group (group 2) was compared with low dose group (group 1), as the control group.

Results
In this study, 80 patients were recruited based on the aforementioned criteria and 69 patients were followed. In group 1, five patients did not comply with their medication order or follow-up. In group 2, five patients were excluded due to personal reasons and one patient due to renal lithiasis. Hence, in group 1, 35 patients (6 male and 29 female) with the mean age of 40.02 (17-75) years old and in group 2, 34 patients (5 male and 29 female) (Figure 1) with the mean age of 39.94 (18-76) years old were studied. The mean course of the disease was 6.62 and 4.24 years for groups 1 and 2.

There was no significant difference in terms of the baseline characteristics (age, gender, BMI, ethnicity, duration of hives, vitamin D level at baseline, atopy, angioedema, ASST) in groups 1 and 2, except for the number of patients with thyroid dysfunction, which was higher in group 2 (P = 0.040) (Table 1).
The difference of week 6 and 12 was significant in group 1 \( (P < 0.0001) \); however, this difference was not significant in group 2. Comparing two groups of the study, the mean USS score was significantly decreased in group 2 at week 6 \( (P = 0.010) \); however, no significant difference was observed at week 12 between groups 1 and 2.

### Medication score for CU

At the baseline, the medication score was not statistically different in groups 1 and 2. The medication score was significantly reduced to 3.37 and 5.17 in groups 1 and 2 \( (P < 0.0001) \) throughout the study. In both groups the decrement in medication score was statistically significant at both weeks 6 and 12, compared to baseline \( (P \leq 0.0001) \); and at week 12, compared to week 6, as well \( (P \leq 0.0001 \text{ and } P = 0.004 \text{ for groups 1 and 2}) \). However, no significant difference in medication score was observed between groups 1 and 2. Data are presented in Figure 2C.

### Questionnaires

At the beginning of the study, mean CU-QoL total scores were not statistically different between groups 1 and 2 (Figure 2A). At the end of the study, total CU-QoL scores were significantly reduced in each group \( (P < 0.0001) \): 30.64% and 42.99% reduction in groups 1 and 2. In both groups, the observed decrement in CU-QoL score was significant at weeks 6 and 12, compared to baseline \( (P < 0.0001) \). The decrement at week 12 was also significant compared to week 6 in low dose \( (P = 0.006) \) and high dose groups \( (P = 0.016) \). Comparing low and high dose groups, a significant reduction in mean CU-QoL score was observed in high dose group at weeks 6 \( (P = 0.005) \) and 12 \( (P = 0.007) \), compared to low dose group.

As shown in Figure 2B, at the beginning of the study, the mean USS total scores were not statistically different between group 1 and 2. At the end of the study, USS means total score was significantly reduced in each group \( (P < 0.0001) \): 50.05% and 67.58% reduction in group 1 and 2. Significant difference was observed between baseline with weeks 6 and 12 in both groups \( (P < 0.0001) \). The difference of week 6 and 12 was significant in group 1 \( (P < 0.0001) \); however, this difference was not significant in group 2. Comparing two groups of the study, the mean USS score was significantly decreased in group 2 at week 6 \( (P = 0.010) \); however, no significant difference was observed at week 12 between groups 1 and 2.
Chronic urticaria: VitD add-on therapy

Figure 2. The effect of low dose (4200 IU/week) and high dose (28000 IU/week) of vitamin D on total score of chronic urticaria quality of life (CU-QoL) (2A), Total score of urticaria symptom severity (USS) (2B) and Total medication score (2C). 25(OH)D level (2D) is presented at baseline, week 6 and week 12. The significant differences are assigned by *. Quality of life score was significantly reduced over the course of study and decrement in group 2 score was significant compared to group 1 at both weeks 6 ($P = 0.005$) and 12 ($P = 0.007$). Both groups showed significantly reduced total urticaria severity score and decrement in group 2 score was significant compared to group 1 at week 6 ($P = 0.010$). Medication score was significantly reduced over the course of study, with no significant difference between groups. 25-hydroxyvitamin D levels were elevated significantly over the course of 12 weeks in both groups; the elevation in group 2 was significantly higher than group 1 at week 12 ($P = 0.002$).

**Lab data**

25(OH)D levels

Deficiency in 25(OH)D level was observed in 65.21% of the patients ($< 20$ ng/L). Although at the baseline, the mean level of vitamin D was higher in group 1, the difference with group 2 was not statistically significant. In both groups, the increment in 25(OH)D level was significant at weeks 6 ($P = 0.002$ and $P < 0.0001$ for groups 1 and 2) and 12 ($P < 0.0001$), compared to baseline; also, the observed increment at week 6 was statistically significant compared to week 12 ($P < 0.0001$). The mean level of vitamin D had significantly increased in each group ($P < 0.0001$); however, the increment was significantly higher in group 2 at week 12 ($P = 0.002$) (**Figure 2D**).

**Anti TPO level**

High TPO levels were observed in 23.18% of the patients. Comparing the USS and CU-QoL total scores in groups with normal and high levels of anti TPO ($> 34$ IU/mL), no significant difference was recorded at the baseline and also weeks 6 and 12 between groups (**Table S1**).

**ASST test**

Intradermal ASST test was positive in 37.68% of the patients. Comparing the USS and CU-QoL total scores in groups with positive and negative ASST test, no significant difference was observed at the baseline and also at weeks 6 and 12 between groups (**Table S2**).

**Angioedema**

The history of angioedema was recorded in 68.11% of the patients. The total CU-QoL and USS scores were compared between groups with and without angioedema. Although at the baseline, the total CU-QoL and USS scores were significantly higher in patients with angioedema, ($P = 0.002$, $P = 0.003$);
**Table S1. Total score of urticarial symptom severity (USS) and chronic urticarial quality of life (CU-QoL) in groups one and two, in patients with anti TPO positive and negative responses**

<table>
<thead>
<tr>
<th>Questionnaire</th>
<th>Time</th>
<th>Low dose vitamin D treatment group (4200 IU/week), n = 35</th>
<th>P-value</th>
<th>High dose vitamin D treatment group (28000 IU/week), n = 34</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>Mean total score of questionnaire</td>
<td></td>
<td>Mean total score of questionnaire</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Anti TPO + (n = 7)</td>
<td>Anti TPO – (n = 28)</td>
<td>Anti TPO + (n = 9)</td>
<td>Anti TPO – (n = 25)</td>
</tr>
<tr>
<td>CU-QoL</td>
<td>Baseline</td>
<td>75.00 ± 14.1</td>
<td>66.10 ± 18.9</td>
<td>0.255*</td>
<td>61.77 ± 21.3</td>
</tr>
<tr>
<td></td>
<td>Week 6</td>
<td>61.00 ± 12.9</td>
<td>53.92 ± 21.9</td>
<td>0.422*</td>
<td>36.44 ± 15.5</td>
</tr>
<tr>
<td></td>
<td>Week 12</td>
<td>49.85 ± 14.4</td>
<td>46.39 ± 23.9</td>
<td>0.719*</td>
<td>29.66 ± 8.9</td>
</tr>
<tr>
<td>USS</td>
<td>Baseline</td>
<td>52.85 ± 10.0</td>
<td>48.10 ± 14.3</td>
<td>0.417*</td>
<td>52.22 ± 26.6</td>
</tr>
<tr>
<td></td>
<td>Week 6</td>
<td>36.28 ± 11.7</td>
<td>32.66 ± 17.7</td>
<td>0.613*</td>
<td>20.44 ± 13.1</td>
</tr>
<tr>
<td></td>
<td>Week 12</td>
<td>25.42 ± 13.8</td>
<td>24.26 ± 20.5</td>
<td>0.889*</td>
<td>15.90 ± 25.2</td>
</tr>
</tbody>
</table>

*Student t-test; †Mann-Whitney U test; P-value < 0.017 was considered as significant.

**Table S2. Total score of urticarial symptom severity (USS) and chronic urticarial quality of life (CU-QoL) in groups one and two, in patients with ASST positive and negative responses**

<table>
<thead>
<tr>
<th>Questionnaire</th>
<th>Time</th>
<th>Low dose vitamin D treatment group (4200 IU/week), n = 35</th>
<th>P-value</th>
<th>High dose vitamin D treatment group (28000 IU/week), n = 34</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>Mean total score of questionnaire</td>
<td></td>
<td>Mean total score of questionnaire</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Anti TPO + (n = 12)</td>
<td>ASST – (n = 23)</td>
<td>Anti TPO + (n = 14)</td>
<td>ASST – (n = 20)</td>
</tr>
<tr>
<td>CU-QoL</td>
<td>Baseline</td>
<td>72.58 ± 19.2</td>
<td>65.80 ± 18.4</td>
<td>0.326*</td>
<td>62.85 ± 21.2</td>
</tr>
<tr>
<td></td>
<td>Week 6</td>
<td>55.25 ± 18.4</td>
<td>55.47 ± 22.9</td>
<td>0.977*</td>
<td>37.64 ± 13.7</td>
</tr>
<tr>
<td></td>
<td>Week 12</td>
<td>44.25 ± 18.9</td>
<td>49.28 ± 24.7</td>
<td>0.547*</td>
<td>31.21 ± 13.4</td>
</tr>
<tr>
<td>USS</td>
<td>Baseline</td>
<td>51.16 ± 17.3</td>
<td>47.95 ± 11.9</td>
<td>0.534*</td>
<td>51.35 ± 14.8</td>
</tr>
<tr>
<td></td>
<td>Week 6</td>
<td>33.08 ± 19.9</td>
<td>33.78 ± 15.7</td>
<td>0.912*</td>
<td>20.14 ± 10.7</td>
</tr>
<tr>
<td></td>
<td>Week 12</td>
<td>22.16 ± 21.6</td>
<td>26.11 ± 18.5</td>
<td>0.584*</td>
<td>15.60 ± 25.3</td>
</tr>
</tbody>
</table>

*Student t-test; †Mann-Whitney U test; P-value < 0.017 was considered as significant.

**Table S3. Total score of urticarial symptom severity (USS) and chronic urticarial quality of life (CU-QoL) in groups one and two, in patients with and without angioedema**

<table>
<thead>
<tr>
<th>Questionnaire</th>
<th>Time</th>
<th>Low dose vitamin D treatment group (4200 IU/week), n = 35</th>
<th>P-value</th>
<th>High dose vitamin D treatment group (28000 IU/week), n = 34</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>Mean total score of questionnaire</td>
<td></td>
<td>Mean total score of questionnaire</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Angioedema + (n = 25)</td>
<td>Angioedema – (n = 10)</td>
<td>Angioedema + (n = 22)</td>
<td>Angioedema – (n = 12)</td>
</tr>
<tr>
<td>CU-QoL</td>
<td>Baseline</td>
<td>72.24 ± 16.6</td>
<td>57.00 ± 18.4</td>
<td>0.023*</td>
<td>68.04 ± 17.2</td>
</tr>
<tr>
<td></td>
<td>Week 6</td>
<td>58.08 ± 21.4</td>
<td>48.50 ± 16.7</td>
<td>0.216*</td>
<td>45.18 ± 17.2</td>
</tr>
<tr>
<td></td>
<td>Week 12</td>
<td>49.28 ± 23.2</td>
<td>41.60 ± 19.5</td>
<td>0.364*</td>
<td>35.95 ± 14.7</td>
</tr>
<tr>
<td>USS</td>
<td>Baseline</td>
<td>52.68 ± 13.8</td>
<td>40.00 ± 7.8</td>
<td>0.011**</td>
<td>56.04 ± 16.2</td>
</tr>
<tr>
<td></td>
<td>Week 6</td>
<td>36.92 ± 17.8</td>
<td>24.55 ± 8.6</td>
<td>0.045*</td>
<td>25.72 ± 14.8</td>
</tr>
<tr>
<td></td>
<td>Week 12</td>
<td>27.92 ± 20.5</td>
<td>15.9 ± 12.4</td>
<td>0.097**</td>
<td>18.80 ± 21.6</td>
</tr>
</tbody>
</table>

*Student t-test; †Mann-Whitney U test; P-value < 0.017 was considered as significant.
Discussion

It was reported that chronic urticaria results in considerable socioeconomic burden.9 The mainstay of CU therapy is symptom relief and not disease modifying. Recent researches on urticaria have focused on the underlying immune mechanisms, the involved mediators and mast cell activation pathways; proposing the auto immunity pathways in urticaria pathogenesis.18 Evaluation of vitamin D, with immunomodulatory effects, was considered in CU patients in the present work.

In the present study, in line with a meta-analysis by Tuchinda et al.,13 vitamin D deficiency was significant in CU patients. Based on Table 1, 86.95% of the patients were observed with vitamin D insufficiency/deficiency. Based on the results, it was observed that vitamin D supplementation in CU patients resulted in the reduction of clinical symptoms (USS scores), reduction of medication score, and improvement in QoL (reduction of CU-QoL score). Although these effects were observed in both groups, group 2 patients who received higher dose of vitamin D (28000 IU/week) were significantly improved compared to group 1 (Figure 2A-C). CU-QoL score was significantly different between the two groups in weeks 6 and 12; however, the significant difference in USS was only observed in week 6. This might be due to the differences in USS and CU-QoL questionnaires criteria. Reduced doses of allergy medications were also recorded; however, no significant differences were observed between groups.

The involvement of autoimmunity mechanisms in CU pathogenesis and the association of CU with positive ASST test14 and high levels of anti TPO antibody were reported in previous studies.15 However, in the present work, positive ASST test and the existence of anti TPO antibodies were not associated with the severity of the disease. In addition, no significant difference was observed in vitamin D effectiveness.

In the present observation, the frequency of angioedema was higher than previous studies at baseline (68.11% (Table S3) vs. 40%).1 However, patients with angioedema presented with higher USS and CU-QoL scores at the baseline, no significant difference was observed in vitamin D effectiveness.

In the study by Tuchinda et al.,13 adjunctive therapy with higher doses of vitamin D3 for 4-12 weeks (at least 28000 IU/week) for patients with vitamin D deficiency was suggested. The recommended dose for vitamin D3 is 140000 IU/week (for 6 weeks). The results of the present randomized clinical study were in accordance with other studies, which reported the effects of vitamin D on the reduction of CU symptoms. In the study by Goetz et al.,16 63 patients with idiopathic skin disorders (rash, urticarial, angioedema) were followed, of which 90% had low levels of vitamin D (< 32 ng/mL). Following the application of 50000 IU vitamin D/week over 8-12 weeks, the symptoms were reduced in 70% of the patients. In the study by Boonpiyathad et al.,17 (20000 IU/day of vitamin D3, 6 weeks) and Oguz Topal et al.,18 (30000 IU/month of vitamin D3 for 3 months) the urticarial activity score (UAS) and dermatology life quality index (DLQI) were reduced significantly following vitamin D supplementation.

This study was compared with the study by Rorie et al. in which the effect of vitamin D (600 IU/day and 4000 IU/day) for CU patients was determined.20 The severity of clinical symptoms was reduced and QoL has improved; however, no significant change was observed in the required dose of allergy medications. In the group receiving low dose of vitamin D (600 IU/day), the recorded level of vitamin D was not elevated significantly at the end of the study, compared to its baseline level. On the contrary, in our study the vitamin D level had increased, using low dose of vitamin D (4000 IU/week). This might be due to the difference in the baseline level of vitamin D, which was lower in both groups of the present study. Due to the nonlinear kinetic of vitamin D elevation, the elevation slope in the patients with lower level of vitamin D would be higher.23 Another difference is higher mean BMI in the study by Rorie et al.26 (Table 1). Patients with higher BMI require higher dosage of vitamin D.29

There are confounding variables in vitamin D level such as ethnicity, geographical region and cultural beliefs which affect sunlight exposure and the amount of produced vitamin D. Difference of melanin pigmentations is another factor. This study was conducted in south Iran with specific cultural and geographical background.

There are some limitations to this study. The number of subjects was limited and it was not a placebo-controlled study. To find out whether vitamin D add-on therapy is efficient to improve CU symptoms, further placebo-controlled studies with larger sample size in various cultural and geographical conditions are warranted.

Conclusion

Based on this study, it might be concluded that using high dose of vitamin D (28000 IU/week) as add-on therapy results in the reduction of CU symptoms severity and the required doses of allergy medications.

Acknowledgments

The authors would like to thank the staff of tertiary center of immunology and allergy, Ms. Kazemi and Ms. Firouzbabadi. The authors wish to thank Mr. H. Argasi at the Research Consultation Center (RCC) of Shiraz University of Medical Sciences for his invaluable assistance in editing this manuscript. This study was supported by Shiraz University of Medical Sciences, Shiraz, Iran. The authors declare no conflict of interest. SHN, SA, FM, HE, NE contributed to the study conception; HE and FM supervised the study; SHN and SA designed the study and contributed to data interpretation and critical revision of the manuscript; FM carried out the experiment, analyzed data and drafted the manuscript; HE and NE were contributed in data analysis and manuscript preparation. All authors have read and approved the manuscript.

References


